If PSMA radioligands are utilized in the treatment of prostate cancer at earlier stages, further follow-up will necessary to determine potential long-term (over 2 years) toxicity after therapy, as other small peptide radionuclides have long-term kidney effects [45]. The gene discussed is FOLH1; the disease is Familial prostate cancer.